Understanding the neurobiology of many neuropsychiatric disorders – such as schizophrenia, major depression and Alzheimer’s – will require novel quantitative biological approaches. Currently, clinical diagnosis is still dependent on the convention-based clustering of qualitative clinical symptoms.
The PRISM consortium is implementing an innovative transdiagnostic approach to link symptoms to biology using a quantitative approach and in doing so to accelerate the discovery and development of new and better treatments for patients.
In this series of six videos, you’ll discover more about PRISM and its aims! In the first video Martien Kas, the project co-ordinator, introduces the project.